The landscape of biologics discovery is rapidly evolving, driven by breakthroughs in AI, an influx of high-quality datasets, and regulatory momentum supporting in silico approaches. As industry leaders look to streamline R&D and de-risk development, there is a critical need for cutting-edge tools in modeling, characterization, screening, and developability.

The 10th anniversary of the CDD for Biologics Summit united 50+ decision-makers and industry experts from pharma and biotech to share their unfiltered lessons learned from validating and training computational models to streamline novel target validation, enhance biologics design and empower developability predictions.

This was the go-to forum for innovators across pharma and biotech to showcase current pipeline developments that can enable faster, smarter, and more scalable therapeutic design.

Diving into the latest industry applications of computational models, including physics-based, generative AI, and de novo design across multiple large molecules, including peptides, ADCs, bispecific T-cell engagers, multi-specifics, vaccines, and more.